Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001683168-25-003313 0001030743 XXXXXXXX LIVE 17 COMMON STOCK, PAR VALUE $0.01 PER SHARE 09/03/2026 false 0000798287 693149106 PAMT CORP 297 WEST HENRI DE TONTI BLVD TONTITOWN AR 72770 Matthew T. Moroun (586) 939-7000 12225 STEPHENS ROAD WARREN MI 48089 0001030743 N Matthew T. Moroun a OO N X1 0.00 6011.00 16001896.00 6011.00 16007907.00 N 76.4 IN * Rows 8 and 10 consist of 6,011 shares of the Issuer's Common Stock owned by Matthew T. Moroun's son, Matthew J. Moroun. Neither the filing of this report nor any of its contents shall be deemed an admission that Matthew T. Moroun is the beneficial owner of such shares for purposes of Section 13(d) of the Act or for any other purpose. ** Row 9 consists of 15,695,848 shares of the Issuer's Common Stock beneficially owned by the 2020 Irrevocable Lindsay S. Moroun Trust dated November 24, 2020 ("2020 Lindsay Moroun Trust"), and 306,048 shares beneficially owned by the 2020 Irrevocable Agnes Anne Moroun Trust ("2020 AAM Trust"). Matthew T. Moroun serves as trustee of each of these two trusts. Sole voting power over the shares held by the 2020 Lindsay Moroun Trust and the 2020 AAM Trust is held by a special trustee, Frederick P. Calderone. *** Row 11 consists of 15,695,848 shares of the Issuer's Common Stock beneficially owned by the 2020 Lindsay Moroun Trust, 306,048 shares beneficially owned by the 2020 AAM Trust, and 6,011 shares owned by Matthew T. Moroun's son, Matthew J. Moroun. Neither the filing of this report nor any of its contents shall be deemed an admission that Matthew T. Moroun is the beneficial owner of the shares owned by Matthew J. Moroun for purposes of Section 13(d) of the Act or for any other purpose. Y Grantor Trust for Matthew T. Moroun and DuraRock Underwriters, Ltd. OO N X1 0.00 0.00 0.00 0.00 0.00 N 0 OO Y 2020 Irrevocable Lindsay S. Moroun Trust, dated November 24, 2020 a OO N X1 15695848.00 0.00 15695848.00 0.00 15695848.00 N 74.9 OO 0001202708 N Frederick P. Calderone b OO N X1 16012532.00 0.00 10636.00 0.00 16012532.00 N 76.5 IN * Rows 7 and 11 consist of 10,636 shares of the Issuer's Common Stock owned directly by Frederick P. Calderone, individually, 15,695,848 shares beneficially owned by the 2020 Lindsay Moroun Trust, and 306,048 shares beneficially owned by the 2020 AAM Trust. Frederick P. Calderone serves as special trustee of each of these trusts with sole voting power over the shares held by each trust. Matthew T. Moroun serves as trustee of these trusts with sole investment power over the shares held by each trust. COMMON STOCK, PAR VALUE $0.01 PER SHARE PAMT CORP 297 WEST HENRI DE TONTI BLVD TONTITOWN AR 72770 This Amendment No. 17 amends and supplements the statement on Schedule 13D filed on January 15, 1997, as amended by the Amendment No. 1 filed on March 8, 2002, Amendment No. 2 filed on March 21, 2002, Amendment No. 3 filed on March 6, 2009, Amendment No. 4 filed on March 23, 2009, Amendment No. 5 filed on January 29, 2014, Amendment No. 6 filed on January 29, 2015, Amendment No. 7 filed on May 2, 2016, Amendment No. 8 filed on April 7, 2017, Amendment No. 9 filed on December 6, 2017, Amendment No. 10 filed on July 5, 2018, Amendment No. 11 filed on July 26, 2019, Amendment No. 12 filed on May 12, 2023, Amendment No. 13 filed on August 3, 2023, Amendment No. 14 filed on July 31, 2024, Amendment No. 15 filed on May 9, 2025, and Amendment No. 16 filed on September 15, 2025 (as amended, the "Schedule 13D"). Each Item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D. Except as otherwise set forth herein, this Amendment No. 17 does not modify any of the information previously reported by the Reporting Persons in the Schedule 13D. Item 3 of the Schedule 13D is hereby amended and supplemented by inserting the following paragraphs after the last paragraph thereof: On May 8, 2026, Matthew J. Moroun received 1,453 shares of Common Stock from the Issuer upon his election to receive stock in lieu of cash for a portion of the Issuer's annual retainer for non-employee directors. On September 3, 2026, Matthew T. Moroun sold 3,268,000 shares of Common Stock of the Issuer beneficially owned by him to the 2020 Lindsay Moroun Trust, for which Matthew T. Moroun serves as trustee and Frederick P. Calderone serves as special trustee. Prior to the sale, on August 18, 2026, these 3,268,000 shares were transferred by the Moroun Grantor Trust to Matthew T. Moroun, as beneficiary of such trust. The source of funds for the purchase of these shares by the 2020 Lindsay Moroun Trust was an interest-bearing note to Matthew T. Moroun. The purchase price was $31,226,000 based on the number of shares multiplied by a per share price of $9.555. The per share price was determined by an independent third party using the average of the high and low prices of the Issuer's Common Stock as reported on the Nasdaq Stock Market on September 3, 2026, adjusted for an applicable block-trade discount. Item 4 of the Schedule 13D is hereby amended and supplemented by inserting the following paragraph after the last paragraph thereof: The transaction described in Item 3 of this Amendment No. 17 resulted in the Moroun Grantor Trust no longer beneficially owning any shares of Common Stock of the Issuer and in increases in the percentages of outstanding shares of Common Stock beneficially owned by the 2020 Lindsay Moroun Trust and Frederick P. Calderone, respectively, since the filing of Amendment No. 16 to this Schedule 13D. The transaction on September 3, 2026, as described in Item 3, was effected for ownership succession purposes. The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by each Reporting Person are stated in Items 11 and 13 on the cover page for each such Reporting Person. The percentage of shares of Common Stock beneficially owned by each Reporting Person is based on 20,942,257 shares of Common Stock outstanding as of July 20, 2026, as disclosed in the Issuer's most recent Quarterly Report on Form 10-Q filed on August 7, 2026. Except for the transaction on September 3, 2026, as described in Item 3 of this Amendment No. 17, the Reporting Persons have not engaged in any transactions in the Common Stock during the past 60 days. Matthew T. Moroun's son, Matthew J. Moroun, has the right to receive or the power to direct the receipt of dividends from, and the proceeds from the sale of, 6,011 shares held by him which are reported as beneficially owned by Matthew T. Moroun. Neither the filing of this report nor any of its contents shall be deemed an admission that Matthew T. Moroun is the beneficial owner of such shares for purposes of Section 13(d) of the Act or for any other purpose. Shares beneficially owned by the 2020 Lindsay Moroun Trust and the 2020 AAM Trust are held for the benefit of members of the Moroun family. Frederick P. Calderone, in his capacity as special trustee of the 2020 Lindsay Moroun Trust and the 2020 AAM Trust, does not have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares held by the 2020 Lindsay Moroun Trust or the 2020 AAM Trust. The Moroun Grantor Trust ceased to be the beneficial owner of more than 5.0% of the outstanding shares of the Issuer on August 18, 2026. Item 6 of the Schedule 13D is hereby amended and supplemented by inserting the following after the last paragraph thereof: In connection with Matthew T. Moroun's sale of 3,268,000 shares of Common Stock on September 3, 2026, the 2020 Lindsay Moroun Trust issued an interest-bearing promissory note to Matthew T. Moroun for $31,226,000, payable in monthly installments through September 2, 2035. 1. Purchase Agreement, dated September 3, 2026, by and between Matthew T. Moroun, individually, and the 2020 Irrevocable Lindsay S. Moroun Trust Under Agreement dated November 24, 2020. 2. Promissory Note dated September 3, 2026 by the 2020 Irrevocable Lindsay S. Moroun Trust Under Agreement dated November 24, 2020 in favor of Matthew T. Moroun, individually. 3. Joint Filing Agreement, dated as of August 3, 2023, among Matthew T. Moroun, the Moroun Grantor Trust, the 2020 Lindsay Moroun Trust, and Frederick P. Calderone (incorporated by reference to Exhibit 3 to the Schedule 13D/A Amendment No. 13, filed on August 3, 2023 (file number 005-39193)). 4. Voting Agreement, dated as of September 11, 2025, between Matthew T. Moroun, Individually and as Trustee of the Moroun Grantor Trust, and Frederick P. Calderone, as Special Trustee of the 2020 Lindsay Moroun Trust (incorporated by reference to Exhibit 4 to the Schedule 13D/A Amendment No. 16, filed on September 15, 2025 (file number 005-39193)). Matthew T. Moroun /s/ Matthew T. Moroun Matthew T. Moroun 09/08/2026 Grantor Trust for Matthew T. Moroun and DuraRock Underwriters, Ltd. /s/ Matthew T. Moroun Matthew T. Moroun, Trustee 09/08/2026 2020 Irrevocable Lindsay S. Moroun Trust, dated November 24, 2020 /s/ Matthew T. Moroun Matthew T. Moroun, Trustee 09/08/2026 /s/ Frederick P. Calderone Frederick P. Calderone, Special Trustee 09/08/2026 Frederick P. Calderone /s/ Frederick P. Calderone Frederick P. Calderone 09/08/2026